sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;
|
tetracycline
|
colestipol hydrochloride
|
MECHANISM
|
Colestipol_ddi.xml
|
DDI-DrugBank.d345.s11
|
DDI-DrugBank.d345.s11.p4
|
Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.
|
enoxacin
|
bismuth subsalicylate
|
ADVISE
|
Enoxacin_ddi.xml
|
DDI-DrugBank.d395.s1
|
DDI-DrugBank.d395.s1.p0
|
Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
|
Chlorotrianisene
|
warfarin
|
INT
|
Chlorotrianisene_ddi.xml
|
DDI-DrugBank.d446.s0
|
DDI-DrugBank.d446.s0.p12
|
Concomitant administration of other sympathomimetic agents may potentiate the undesirable effects of FORADIL.
|
sympathomimetic agents
|
FORADIL
|
EFFECT
|
Formoterol_ddi.xml
|
DDI-DrugBank.d103.s2
|
DDI-DrugBank.d103.s2.p0
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
polymyxins
|
anesthetics
|
NONE
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p81
|
Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.
|
glutamic acid HCl
|
amphetamines
|
MECHANISM
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s0
|
DDI-DrugBank.d236.s0.p19
|
(Thiazides may decrease arterial responsiveness to norepinephrine.
|
Thiazides
|
norepinephrine
|
EFFECT
|
Hydroflumethiazide_ddi.xml
|
DDI-DrugBank.d17.s28
|
DDI-DrugBank.d17.s28.p0
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
nondepolarizing agents
|
antibiotics
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p1
|
Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).
|
Gleevec
|
pimozide
|
ADVISE
|
Imatinib_ddi.xml
|
DDI-DrugBank.d115.s9
|
DDI-DrugBank.d115.s9.p1
|
Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).
|
Diphenhydramine hydrochloride
|
CNS depressants
|
EFFECT
|
Diphenhydramine_ddi.xml
|
DDI-DrugBank.d296.s0
|
DDI-DrugBank.d296.s0.p1
|
Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.
|
heroin
|
methadone
|
EFFECT
|
Heroin_ddi.xml
|
DDI-DrugBank.d514.s2
|
DDI-DrugBank.d514.s2.p5
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
niacinamide
|
valproate
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p312
|
Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.
|
oxyphenbutazone
|
aspirin
|
EFFECT
|
Aspirin_ddi.xml
|
DDI-DrugBank.d443.s3
|
DDI-DrugBank.d443.s3.p8
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
fentanyl
|
tranquilizers
|
EFFECT
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p27
|
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
|
LEVSIN
|
phenothiazines
|
EFFECT
|
Hyoscyamine_ddi.xml
|
DDI-DrugBank.d142.s0
|
DDI-DrugBank.d142.s0.p3
|
Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
|
anesthetics
|
tricyclic antidepressants
|
ADVISE
|
Imipramine_ddi.xml
|
DDI-DrugBank.d77.s2
|
DDI-DrugBank.d77.s2.p8
|
Phenothiazines - Taking piperazine and a phenothiazine together may increase the risk of convulsions (seizures).
|
Phenothiazines
|
phenothiazine
|
NONE
|
Piperazine_ddi.xml
|
DDI-DrugBank.d326.s0
|
DDI-DrugBank.d326.s0.p1
|
Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
|
Nabilone
|
alcohol
|
ADVISE
|
Nabilone_ddi.xml
|
DDI-DrugBank.d552.s0
|
DDI-DrugBank.d552.s0.p2
|
Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.
|
INSPRA
|
lithium
|
ADVISE
|
Eplerenone_ddi.xml
|
DDI-DrugBank.d20.s9
|
DDI-DrugBank.d20.s9.p2
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
pyrazolones
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p40
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
cimetidine
|
nicotinamide
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p89
|
Concomitant use of barbiturates usually depresses griseofulvin activity and may necessitate raising the dosage.
|
barbiturates
|
griseofulvin
|
EFFECT
|
Griseofulvin_ddi.xml
|
DDI-DrugBank.d83.s1
|
DDI-DrugBank.d83.s1.p0
|
Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.
|
celecoxib
|
fluconazole
|
INT
|
Celecoxib_ddi.xml
|
DDI-DrugBank.d172.s6
|
DDI-DrugBank.d172.s6.p0
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
Tylenol
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p1
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
pentoxifylline
|
warfarin sodium
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1331
|
This decrease in bioavailability was about 5% when gabapentin was administered 2 hours after Maalox.
|
gabapentin
|
Maalox
|
MECHANISM
|
Gabapentin_ddi.xml
|
DDI-DrugBank.d438.s38
|
DDI-DrugBank.d438.s38.p0
|
It is desirable to monitor TCAplasma levels whenever an agent of the tricyclic antidepressant class including Anafranil is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).
|
TCA
|
Anafranil
|
NONE
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s23
|
DDI-DrugBank.d238.s23.p1
|
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
|
isoniazid
|
thyroid hormones
|
NONE
|
Insulin recombinant_ddi.xml
|
DDI-DrugBank.d313.s2
|
DDI-DrugBank.d313.s2.p86
|
Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated.
|
Amprenavir
|
25-O-desacetylrifabutin
|
MECHANISM
|
11158747.xml
|
DDI-MedLine.d3.s14
|
DDI-MedLine.d3.s14.p1
|
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
sulfonylureas
|
chloramphenicol
|
EFFECT
|
Glibenclamide_ddi.xml
|
DDI-DrugBank.d178.s0
|
DDI-DrugBank.d178.s0.p3
|
Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.
|
rifabutin
|
efavirenz
|
MECHANISM
|
Efavirenz_ddi.xml
|
DDI-DrugBank.d531.s5
|
DDI-DrugBank.d531.s5.p5
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NUROMAX
|
antibiotics
|
EFFECT
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s5
|
DDI-DrugBank.d267.s5.p0
|
Antacids: Concomitant administration of aluminum and magnesium hydroxides does not interfere with absorption of meclofenamate sodium.
|
aluminum hydroxide
|
meclofenamate sodium
|
NONE
|
Meclofenamic acid_ddi.xml
|
DDI-DrugBank.d113.s7
|
DDI-DrugBank.d113.s7.p4
|
Flavoridin alone was found to have no effect on CAS, but can completely block contortrostatin-induced phosphorylation of this protein in MDA-MB-435 cells.
|
Flavoridin
|
contortrostatin
|
EFFECT
|
10978746.xml
|
DDI-MedLine.d69.s5
|
DDI-MedLine.d69.s5.p0
|
Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
|
ritonavir
|
cisapride
|
MECHANISM
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s12
|
DDI-DrugBank.d237.s12.p7
|
Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
|
anesthetics
|
procainamide
|
NONE
|
Bentiromide_ddi.xml
|
DDI-DrugBank.d537.s0
|
DDI-DrugBank.d537.s0.p65
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
diflunisal
|
triclofos sodium
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p815
|
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.
|
dexamethasone
|
saquinavir
|
MECHANISM
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s30
|
DDI-DrugBank.d124.s30.p8
|
Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.
|
iron
|
Ibandronate
|
MECHANISM
|
Ibandronate_ddi.xml
|
DDI-DrugBank.d440.s1
|
DDI-DrugBank.d440.s1.p9
|
Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.
|
butorphanol
|
alcohol
|
EFFECT
|
Butorphanol_ddi.xml
|
DDI-DrugBank.d246.s0
|
DDI-DrugBank.d246.s0.p1
|
Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
|
salicylates
|
antidiabetic drugs
|
EFFECT
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s14
|
DDI-DrugBank.d460.s14.p14
|
Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.
|
zaleplon
|
erythromycin
|
MECHANISM
|
Zaleplon_ddi.xml
|
DDI-DrugBank.d324.s20
|
DDI-DrugBank.d324.s20.p0
|
- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
|
Sparine
|
trimeprazine
|
NONE
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s21
|
DDI-DrugBank.d179.s21.p253
|
At steady state, VIOXX 50 mg once daily had no effect on the anti-platelet activity of low-dose (81 mg once daily) aspirin, as assessed by ex vivo platelet aggregation and serum TXB2 generation in clotting blood.
|
VIOXX
|
aspirin
|
NONE
|
Rofecoxib_ddi.xml
|
DDI-DrugBank.d210.s6
|
DDI-DrugBank.d210.s6.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
antibiotics
|
tolbutamide
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p352
|
Ocupress should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally because of the potential for additive effects on systemic beta-blockade.
|
Ocupress
|
beta-adrenergic blocking agent
|
ADVISE
|
Carteolol_ddi.xml
|
DDI-DrugBank.d502.s0
|
DDI-DrugBank.d502.s0.p0
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
dopamine agonists
|
iodine-containing compounds
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p355
|
Anafranil should not be used with MAO inhibitors.
|
Anafranil
|
MAO inhibitors
|
ADVISE
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s2
|
DDI-DrugBank.d238.s2.p0
|
Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide.
|
Starlix
|
tolbutamide
|
MECHANISM
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s1
|
DDI-DrugBank.d460.s1.p0
|
Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.
|
dextromethorphan
|
valdecoxib
|
MECHANISM
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s19
|
DDI-DrugBank.d328.s19.p0
|
Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.
|
diltiazem
|
carbamazepine
|
MECHANISM
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s30
|
DDI-DrugBank.d565.s30.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
haloperidol
|
methadone
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p714
|
When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished.
|
ouabain
|
phentolamine
|
EFFECT
|
2857198.xml
|
DDI-MedLine.d56.s5
|
DDI-MedLine.d56.s5.p0
|
Haloperidol: Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.
|
Haloperidol
|
amphetamines
|
EFFECT
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s18
|
DDI-DrugBank.d236.s18.p2
|
Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
|
norepinephrine
|
tricyclic antidepressants
|
ADVISE
|
Imipramine_ddi.xml
|
DDI-DrugBank.d77.s2
|
DDI-DrugBank.d77.s2.p14
|
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.
|
dihydroergotamine
|
AXERT
|
ADVISE
|
Almotriptan_ddi.xml
|
DDI-DrugBank.d299.s1
|
DDI-DrugBank.d299.s1.p8
|
RAPTIVA should not be used with other immunosuppressive drugs.
|
RAPTIVA
|
immunosuppressive drugs
|
ADVISE
|
Efalizumab_ddi.xml
|
DDI-DrugBank.d44.s1
|
DDI-DrugBank.d44.s1.p0
|
Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.
|
reserpine
|
ZEBETA
|
EFFECT
|
Bisoprolol_ddi.xml
|
DDI-DrugBank.d476.s1
|
DDI-DrugBank.d476.s1.p1
|
The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
|
antiparkinsonian drug
|
tricyclic antidepressant
|
EFFECT
|
Chlorpromazine_ddi.xml
|
DDI-DrugBank.d86.s0
|
DDI-DrugBank.d86.s0.p10
|
Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments.
|
iron
|
cobalt
|
MECHANISM
|
7599505.xml
|
DDI-MedLine.d34.s7
|
DDI-MedLine.d34.s7.p1
|
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
|
finasteride
|
HMG-CoA reductase inhibitors
|
NONE
|
Finasteride_ddi.xml
|
DDI-DrugBank.d209.s3
|
DDI-DrugBank.d209.s3.p11
|
Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.
|
Epinephrine
|
guanethidine
|
EFFECT
|
Epinephrine_ddi.xml
|
DDI-DrugBank.d247.s9
|
DDI-DrugBank.d247.s9.p0
|
Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45 (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
|
ergot alkaloid class
|
antibiotics
|
NONE
|
Dihydroergotamine_ddi.xml
|
DDI-DrugBank.d410.s5
|
DDI-DrugBank.d410.s5.p20
|
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
|
NaFlu
|
insulin
|
NONE
|
11154900.xml
|
DDI-MedLine.d76.s10
|
DDI-MedLine.d76.s10.p8
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
thyroid drugs
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p48
|
Hypotension Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.
|
diuretics
|
captopril
|
EFFECT
|
Captopril_ddi.xml
|
DDI-DrugBank.d175.s0
|
DDI-DrugBank.d175.s0.p4
|
Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.
|
ZYVOX
|
antidepressants
|
EFFECT
|
Linezolid_ddi.xml
|
DDI-DrugBank.d441.s6
|
DDI-DrugBank.d441.s6.p1
|
Catecholamine-depleting drugs (eg, reserpine) may have an additive effect when given with beta-blocking agents.
|
reserpine
|
beta-blocking agent
|
EFFECT
|
Atenolol_ddi.xml
|
DDI-DrugBank.d73.s0
|
DDI-DrugBank.d73.s0.p0
|
In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.
|
warfarin
|
fosinopril
|
NONE
|
Fosinopril_ddi.xml
|
DDI-DrugBank.d176.s12
|
DDI-DrugBank.d176.s12.p53
|
Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.
|
phenobarbital
|
bexarotene
|
MECHANISM
|
Bexarotene_ddi.xml
|
DDI-DrugBank.d467.s3
|
DDI-DrugBank.d467.s3.p5
|
When administered concurrently, the following drugs may interact with amphotericin B: Antineoplastic agents: may enhance the potential for renal toxicity, bronchospasm and hypotension.
|
amphotericin B
|
Antineoplastic agents
|
EFFECT
|
Amphotericin B_ddi.xml
|
DDI-DrugBank.d318.s0
|
DDI-DrugBank.d318.s0.p0
|
Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
|
grepafloxacin
|
codeine
|
NONE
|
Chlorpromazine_ddi.xml
|
DDI-DrugBank.d86.s1
|
DDI-DrugBank.d86.s1.p66
|
In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.
|
docetaxel
|
terfenadine
|
MECHANISM
|
Docetaxel_ddi.xml
|
DDI-DrugBank.d371.s1
|
DDI-DrugBank.d371.s1.p1
|
Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.
|
non-steroidal anti-inflammatory drugs
|
cyclosporine
|
EFFECT
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s14
|
DDI-DrugBank.d82.s14.p0
|
Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
|
ACE inhibitors
|
beta blockers
|
NONE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s35
|
DDI-DrugBank.d558.s35.p2
|
If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.
|
magnesium hydroxide
|
TIKOSYN
|
NONE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s5
|
DDI-DrugBank.d558.s5.p34
|
Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
|
aminosalicylic acid
|
furosemide
|
NONE
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s0
|
DDI-DrugBank.d260.s0.p71
|
Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.
|
INVIRASE
|
ritonavir
|
ADVISE
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s28
|
DDI-DrugBank.d124.s28.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
anabolic steroids
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p4
|
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
|
multivitamin preparations
|
FACTIVE
|
ADVISE
|
Gemifloxacin_ddi.xml
|
DDI-DrugBank.d347.s7
|
DDI-DrugBank.d347.s7.p38
|
In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.
|
warfarin
|
digoxin
|
NONE
|
Irbesartan_ddi.xml
|
DDI-DrugBank.d27.s4
|
DDI-DrugBank.d27.s4.p1
|
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.
|
ergotamine
|
naratriptan
|
ADVISE
|
Naratriptan_ddi.xml
|
DDI-DrugBank.d478.s1
|
DDI-DrugBank.d478.s1.p3
|
Increases in prothrombin time have been noted in patients receiving long- term warfarin therapy after flutamide was initiated.
|
warfarin
|
flutamide
|
EFFECT
|
Flutamide_ddi.xml
|
DDI-DrugBank.d442.s0
|
DDI-DrugBank.d442.s0.p0
|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
didanosine
|
sulfamethoxazole
|
NONE
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p63
|
Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.
|
Cerubidine
|
doxorubicin
|
EFFECT
|
Daunorubicin_ddi.xml
|
DDI-DrugBank.d69.s0
|
DDI-DrugBank.d69.s0.p0
|
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
|
fluoxetine
|
monoamine oxidase (MAO) inhibitors
|
NONE
|
Insulin recombinant_ddi.xml
|
DDI-DrugBank.d313.s1
|
DDI-DrugBank.d313.s1.p34
|
Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.
|
carbamazepine
|
doxycycline
|
MECHANISM
|
Doxycycline_ddi.xml
|
DDI-DrugBank.d500.s4
|
DDI-DrugBank.d500.s4.p4
|
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
|
antidepressants
|
flecainide
|
NONE
|
Duloxetine_ddi.xml
|
DDI-DrugBank.d548.s9
|
DDI-DrugBank.d548.s9.p18
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
Neoral
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p21
|
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.
|
dipyridamole
|
Activase
|
EFFECT
|
Alteplase_ddi.xml
|
DDI-DrugBank.d508.s1
|
DDI-DrugBank.d508.s1.p13
|
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.
|
acetaminophen
|
theophylline
|
NONE
|
11206047.xml
|
DDI-MedLine.d111.s5
|
DDI-MedLine.d111.s5.p0
|
The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
|
fentanyl
|
nelfinavir
|
MECHANISM
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s2
|
DDI-DrugBank.d170.s2.p5
|
A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.
|
selective serotonin reuptake inhibitors
|
Imitrex
|
EFFECT
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s4
|
DDI-DrugBank.d423.s4.p1
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
oxyphenbutazone
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p34
|
Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption.
|
magnesium trisilicate
|
nitrofurantoin
|
MECHANISM
|
Nitrofurantoin_ddi.xml
|
DDI-DrugBank.d276.s0
|
DDI-DrugBank.d276.s0.p2
|
- Methotrexate (e.g., Mexate) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate
|
methotrexate
|
sulfapyridine
|
EFFECT
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s38
|
DDI-DrugBank.d179.s38.p7
|
Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
|
amiodarone
|
digoxin
|
MECHANISM
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s2
|
DDI-DrugBank.d450.s2.p22
|
Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
|
narcotic analgesics
|
meperidine
|
NONE
|
Biperiden_ddi.xml
|
DDI-DrugBank.d401.s0
|
DDI-DrugBank.d401.s0.p17
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
dalfopristin
|
isoniazid
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p126
|
Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.
|
estazolam
|
ketoconazole
|
ADVISE
|
Estazolam_ddi.xml
|
DDI-DrugBank.d338.s6
|
DDI-DrugBank.d338.s6.p0
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.